(Information sent by the signatory company)
- MolecuLight featured in Vizient Tech Watch as key technology to visualize bacterial load and help reduce surgical site infections
The article follows on from MolecuLight's receipt of an innovative technology contract from Vizient last year.
PITTSBURGH, Dec. 6, 2022 /PRNewswire/ -- MolecuLight Corp., the leader in point-of-care fluorescence imaging for the detection of wounds containing elevated bacterial loads, is featured in Vizient's recently launched Tech Watch publication as a key technology to visualize the bacterial load and its locations, and help reduce the surgical site. Infections The article, "Fluorescence Imaging: New Technology Enables Bacterial Assessment of Surgical Wounds at the Point-of-Care" appears in Vizient's Tech Watch (Medical Device) Volume 3 issue, published last week.
The Tech Watch article describes how surgical site infections (SSIs) occur in up to 38% of surgeries1 (depending on anatomical location and type of surgery) and account for 20% of all healthcare-acquired infections. health2. Surgical site infections are also the most costly of these infections, extending the average length of hospital stay by 9.7 days and costing more than $20,000 per patient admission3,4.
Early and accurate diagnosis of infections and post-surgical bacterial loads is essential to allow prompt treatment before the infection worsens. Some cases require laboratory tests to accurately diagnose the bacteria colonizing the wound, allowing harmful bacteria to grow and spread and delaying effective treatments. Test results can take days or weeks to be available, and if positive, it could be too late to prevent infection.
Clinicians need real-time diagnostic tools that they can use at the point of care to help provide immediate information on wound status and potential bacterial load growth. The article argues that MolecuLight imaging helps eliminate unnecessary subjectivity in wound assessment for the presence of harmful bacteria by enabling rapid and accurate visualization of locations of elevated bacterial load in wounds, along with signs and symptoms. clinical. As such, it provides "real-time valuable information to inform clinical decision-making."
A recent reviewed study5 supports this position by demonstrating the benefits of using the MolecuLight to help the clinician visualize the bacterial load in surgical site wounds:
"Clinicians need an objective means of detecting infection or other surgical wound complications without having to rely on subjective judgment," said Kylie Sandy-Hodgetts, PhD, founder and inaugural chair of the International Surgical Wound Complications Advisory Panel (ISWCAP). ).
"MolecuLight fluorescence imaging is poised to change contemporary paradigms of post-surgical wound care due to its ability to quickly and reliably detect bacterial load and visualize contamination at the point of care."
In addition to Vizent's Tech Watch profile, last year the MolecuLight i:X® fluorescence wound imaging device received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance improvement company. big in the country The new breakthrough technology contract for MolecuLight i:X signifies to Vizient members the unique qualities of the device that potentially bring improvements to the healthcare industry.
In addition to Vizent's Tech Watch profile, last year the MolecuLight i:X® fluorescence wound imaging device received an Innovative Technology contract from Vizient, Inc., the largest member-driven healthcare performance improvement company. big in the country The new breakthrough technology contract for MolecuLight i:X signifies to Vizient members the unique qualities of the device that potentially bring improvements to the healthcare industry.
"We have been working with MolecuLight since 2021, when Vizient recognized the company as an award-winning provider through our Innovative Technology Program," explained Tami Maurer, Vice President of Program and Contract Services at Vizient, Inc. "Carefully evaluated and selected by our Board of members of clinical and supply chain professionals, Vizient's Innovative Technology Program recognizes innovative advances in care, enabling healthcare providers to deliver the highest quality care and encouraging manufacturers to continue to pioneer new solutions.
MolecuLight i:X and DX are the only imaging devices for real-time detection of elevated bacterial load in wounds that are FDA and CE and Health Canada cleared. With clinical evidence including more than 60 peer-reviewed publications involving 1,500 patients, they are used by leading wound care centers globally.
About MolecuLight Corp.
MolecuLight Corp. is the US subsidiary of MolecuLight Inc., a privately held medical imaging company that has developed and markets its proprietary fluorescent imaging platform technology in multiple clinical markets. MolecuLight's suite of commercial devices, including the MolecuLight i:X® and DX™ fluorescence imaging systems and accessories, are portable point-of-care imaging devices for real-time detection and localization of bacterial load. in wounds and digital measurement of wounds. MolecuLight procedures performed in the United States benefit from an available reimbursement pathway that includes two CPT® codes for physician work to perform "fluorescence imaging for presence, location, and load of bacteria" and facility payment for the Hospital Outpatient Department (HOPD) and the Ambulatory Surgical Center (ASC) through an Outpatient Payment Classification (APC) assignment. The company is also commercializing its unique fluorescence imaging platform technology to other global markets with relevant unmet needs in food safety, consumer cosmetics, and other key industrial markets.
Images:
Photo - https://mma.prnewswire.com/media/1961836...Photo - https://mma.prnewswire.com/media/1961837...
CONTACTO: Rob Sandler, director de Marketing, MolecuLight Inc., T. 1.647.362.4684, rsandler@moleculight.com; www.moleculight.com
View original content: https://www.prnewswire.com/news-releases/moleculight-aparece-en-vizient-tech-watch-como-tecnologia-clave-para-visualizar-la-carga-bacteriana-301696199.html
